To identify and reduce environmental risks caused by the use of human pharmaceuticals.
1) To identify human pharmaceuticals that are likely to be of concern to aquatic ecosystems, 2) To address the risk for antibiotic resistance promotion in the environment, 3) To propose risk management strategies, in particular, improved regulatory test requirements and wastewater treatment technologies.
- Mistra Pharma
- Mistra Pharma Newsletter
- Identification and reduction of environmental risks caused by human pharmaceuticals. Final report
- Identification and reduction of environmental risks caused by human pharmaceuticals
- Pharmaceuticals in a Healthy Environment MistraPharma Research 2008–2011
- Towards Sustainable Pharmaceuticals in a Healthy Society
- A Healthy Future Pharmaceuticals in a Sustainable Society
- Recommendations for Improving Environmental Risk Assessment of Pharmaceuticals
- Contributions from metabolomics to fish research
- Towards more efficient testing strategies – analyzing the efficiency of toxicity data requirements in relation to the criteria for classification and labelling
- Evolutionary conservation of human drug targets in organisms used for environmental risk assessments
- The Swedish Environmental Classification and Information System for Pharmaceuticals – an empirical investigation of the motivations, intentions, and expectations underlying its development and implementation
- Detection of the antiviral drug oseltamivir in aquatic environments
- Collaboration to reduce the environmental risks of pharmaceuticals. MistraPharma researchers and stakeholders
- Strategies for monitoring the emerging polar organic contaminants in water with emphasis on integrative passive sampling
- Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems
- WikiPharma – a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals
- Comparison of six sewage effluents treated with different treatment technologies. Population level responses in the harpacticoid copepod Nitocra spinipes
- Welcome to the Wikipharma Database!
HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.